Prior to its presentation at the annual JPMorgan Healthcare conference, MAKO Surgical (MAKO)
released some limited information about its fourth-quarter results.
While MAKO avoided the big miss that some investors had feared, and
system placement performance was in line with expectations, utilization
continues to be a meaningful concern for this company.
Q4 Data - Placements Okay, Procedures Less So
For
the fourth quarter of 2012, MAKO Surgical reported that it had sold 15
RIO systems around the world, basically matching Wall Street
expectations. While two of the sales were overseas and appear to have a
meaningful deferred revenue recognition treatment, that's a quibble at
this point. It's worth noting, though, that while this performance
matched expectations, the full-year placement number of 45 was well
below the guidance management gave a year-ago for 56-62 placements this
year.
Read the full article here:
MAKO's Performance Still Pretty "Meh"
No comments:
Post a Comment